BIOLASE Prices $9.75M Offering
BIOLASE, Inc. (NASDAQ:BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common
‘NIO Becomes the Second-Largest BEV Manufacturer in China by Revenue at the Start of 2023’ -Wccftech
https://www.twitter.com/i/status/1612791125458452480
TSR Q2 EPS $0.30 Up From $0.12 YoY, Sales $26.00M Up From $23.86M YoY
TSR (NASDAQ:TSRI) reported quarterly earnings of $0.30 per share. This is a 150 percent increase over earnings of $0.12 per share from the same period last year. The company reported $26.00 million in sales this
Nicola Mining Inc. And Osisko Development Corp. Enter Into Mining And Milliing Profit Share Agreement
Nicola Mining Inc. (TSXV:NIM)(FSE: HLI), (the "Company" or "Nicola") is pleased to announce that it and Osisko Development Corp. (NYSE:ODV) (TSXV:ODV) ("Osisko") have signed a Mining and
Daré Bioscience Announces Pharmacokinetic Results From DARE-HRT1 Phase 1 / 2 Study That Support Potential Pf DARE-HRT1 As Hormone Therapy For Both Vasomotor And Vaginal Symptoms of Menopause
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause
DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal
2seventy bio Announces Expanded Translational Collaboration With Regeneron To Develop New Cell Therapy-Based Combinations Dor Solid Tumors; Regeneron To Invest $20M In 2seventy Equity
Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches
Regeneron Investing $20
‘Smartphone maker Xiaomi to take on Tesla with its first EV’ -SCMP
https://www.scmp.com/business/china-business/article/3205892/smartphone-maker-xiaomi-has-tesla-its-sights-it-reportedly-plans-debut-first-car-model-year-end?module=live&pgtype=homepage
Phillips 66 Reaches Agreement To Acquire Publicly Held Common Units Of DCP Midstream, LP For $41.75/Unit; Will Increase Interest To 86.8%
Phillips 66 (NYSE:PSX) and DCP Midstream, LP ("DCP Midstream") (NYSE:DCP) announced today that they have entered into a definitive agreement pursuant to which Phillips 66 will acquire all of the publicly held
Precision BioSciences Receives Favorable Type C Feedback From FDA On Company’s Chemistry, Manufacturing And Controls Strategies For Late-Stage Development Of Azercabtagene Zapreleucel, Its Lead Allogeneic CAR T Clinical Candidate
- FDA feedback signals the Company's CMC plans shared are in alignment with Agency requirements and expectations
Spruce Biosciences And Kaken Pharmaceutical Announce Exclusive Licensing Agreement To Develop And Commercialize Tildacerfont For CAH In Japan; Spruce To Receive $15M Upfront Payment Plus Milestones And Royalies
Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH)
Deal advances strategy to partner